Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

VYNE Therapeutics (VYNE) Total Liabilities (2016 - 2025)

VYNE Therapeutics (VYNE) has disclosed Total Liabilities for 10 consecutive years, with $2.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Liabilities fell 83.84% year-over-year to $2.4 million, compared with a TTM value of $2.4 million through Dec 2025, down 83.84%, and an annual FY2025 reading of $2.4 million, down 83.84% over the prior year.
  • Total Liabilities was $2.4 million for Q4 2025 at VYNE Therapeutics, down from $5.8 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $59.1 million in Q2 2021 and bottomed at $2.4 million in Q4 2025.
  • Average Total Liabilities over 5 years is $15.2 million, with a median of $9.0 million recorded in 2023.
  • The sharpest move saw Total Liabilities plummeted 88.43% in 2022, then soared 65.58% in 2024.
  • Year by year, Total Liabilities stood at $18.4 million in 2021, then crashed by 49.24% to $9.3 million in 2022, then dropped by 4.23% to $9.0 million in 2023, then soared by 65.58% to $14.8 million in 2024, then plummeted by 83.84% to $2.4 million in 2025.
  • Business Quant data shows Total Liabilities for VYNE at $2.4 million in Q4 2025, $5.8 million in Q2 2025, and $12.3 million in Q1 2025.